Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand.
J Clin Endocrinol Metab. 2010 Apr;95(4):1653-62. doi: 10.1210/jc.2009-2384. Epub 2010 Feb 3.
Uncertainty exists as to the optimal management and monitoring of the skeletal consequences of mild primary hyperparathyroidism (PHPT).
The aim of this study was to determine the effects of surgical treatment, medical treatment and no treatment on bone mineral density (BMD) in mild PHPT.
Our sources were Medline, EMBASE, and Cochrane CENTRAL prior to January 2009, and abstracts from meetings of international bone and mineral societies from 1987-2008.
Eligible studies were of at least 1-yr duration and included more than 10 participants with mild PHPT (serum calcium < 12 mg/dl) who had BMD measured by dual-energy x-ray absorptiometry while being observed without intervention, or treated with antiresorptive therapy or surgery. Primary analysis was of studies of up to 2-yr duration. Secondary analysis was of studies with follow-up beyond 2 yr.
Data were extracted from the text of the retrieved articles or conference abstracts.
Increases in BMD in response to surgical intervention were comparable to those induced by antiresorptive therapies. Significant bone loss was observed in untreated subjects, but the rates of loss ranged from 0.6-1.0%/yr. Analysis of studies reporting data beyond 2 yr of follow-up demonstrated stable increases in BMD after surgery and stable BMD or slow loss (0.1-0.3%/yr) in untreated PHPT.
Surgical treatment and antiresorptive therapies increase BMD in mild PHPT to a similar degree, and each represents a reasonable option in a patient with mild PHPT and low BMD. Rapid bone loss does not occur in untreated mild PHPT, such that monitoring of BMD less frequently than every 1-2 yr is reasonable in individuals for whom intervention is not immediately required.
轻度原发性甲状旁腺功能亢进症(PHPT)骨骼后果的最佳治疗和监测方法仍存在不确定性。
本研究旨在确定手术治疗、药物治疗和不治疗对轻度 PHPT 患者骨密度(BMD)的影响。
我们的资料来源是 2009 年 1 月之前的 Medline、EMBASE 和 Cochrane CENTRAL,以及 1987-2008 年国际骨与矿物质学会会议的摘要。
符合条件的研究持续时间至少为 1 年,包括 10 名以上轻度 PHPT(血清钙<12mg/dl)患者,这些患者在未接受干预的情况下通过双能 X 线吸收法测量了 BMD,或接受了抗吸收治疗或手术。主要分析为持续时间达 2 年的研究。二次分析是对随访时间超过 2 年的研究。
从检索到的文章或会议摘要的文本中提取数据。
手术干预引起的 BMD 增加与抗吸收治疗引起的增加相当。未治疗的患者观察到明显的骨丢失,但丢失率为 0.6-1.0%/yr。对报告超过 2 年随访数据的研究进行分析,结果表明手术后 BMD 持续增加,未治疗的 PHPT 患者 BMD 稳定或缓慢丢失(0.1-0.3%/yr)。
手术治疗和抗吸收治疗可使轻度 PHPT 患者的 BMD 增加到相似程度,对于轻度 PHPT 且 BMD 较低的患者,每种治疗方法都是合理的选择。未治疗的轻度 PHPT 不会发生快速骨丢失,因此对于不需要立即干预的患者,BMD 的监测频率不必每 1-2 年进行一次。